<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04453397</url>
  </required_header>
  <id_info>
    <org_study_id>TNB383B.9001</org_study_id>
    <nct_id>NCT04453397</nct_id>
  </id_info>
  <brief_title>Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>A Single Patient Protocol for TNB-383B, a Bispecific Antibody Targeting BCMA in a Subject With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teneobio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teneobio, Inc.</source>
  <brief_summary>
    <textblock>
      This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple
      myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit
      in MM.
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNB-383B</intervention_name>
    <description>TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adequate bone marrow function

          -  eGFR ≥ 30 mL/min

          -  Total bilirubin ≤ 1.5 × upper limit of normal (ULN)

          -  Serum calcium (corrected for albumin) at or below the ULN range

        Exclusion Criteria:

          -  Candidate for treatment regimens known to provide clinical benefit in MM

          -  Active infection requiring parenteral anti-infective treatment

          -  Any medical or psychiatric condition which in the opinion of the investigator or
             Teneobio Medical Monitor places the subject at an unacceptably high risk for
             toxicities, could interfere with successful or safe delivery of therapy, or could
             interfere with evaluation of the investigational product or interpretation of subject
             safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ben Buelow</last_name>
    <role>Study Chair</role>
    <affiliation>Teneobio, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 26, 2020</study_first_submitted>
  <study_first_submitted_qc>June 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

